Iomai skyrockets 116% on buyout news
Iomai Corp. (Nasdaq:IOMI) shares are skyrocketing 116% after the Gaithersburg, Md.-based biopharmaceutical firm announced it is being bought by Intercell AG for $189 million in a stock-and-cash deal. Intercell, and Austria-based vaccine developer, will pay $6.60 per share, a 126% premium from Monday’s closing price.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
